A site initiation visit for a therapeutical sub-study of TB Sequel took place from the 9 – 11 October 2018 in Mbeya, Tanzania.
The purpose of this clinical trial is to assess the potential role of oral N-acetylcysteine as an adjunctive host-directed therapy in TB.
A total of 110 patients (55 per arm) with drug sensitive pulmonary TB aged 18 to 65 years will be enrolled. Patients will be randomized to receive standard TB treatment with or without N-acetylcysteine.
The local clinicians and investigators were trained in the main study procedures during the SIV and will soon implement this sub-study as a part of TB Sequel.
